Botulinum toxin in children with cerebral palsy

Indian Journal of Pediatrics

Volumn 71, Issue 12, 2004, Pages 1087-1091

  Singhi, Pratibha ^a   Ray, Munni ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Botulinum toxin; Cerebral palsy; Spasticity

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN B;

ACETYLCHOLINE RELEASE; ADJUVANT THERAPY; ANTIBODY TITER; ANTICHOLINERGIC EFFECT; CEREBRAL PALSY; CHILD; CHOLINERGIC NERVE; CLINICAL TRIAL; CLOSTRIDIUM BOTULINUM; DISABILITY; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; DYSTONIA; ELECTROSTIMULATION THERAPY; GAIT DISORDER; HANDICAPPED CHILD; HUMAN; JOINT CONTRACTURE; META ANALYSIS; MOTOR DYSFUNCTION; MUSCLE CONTRACTURE; MUSCLE SPASM; MUSCLE WEAKNESS; ORTHOSIS; PATIENT SELECTION; PHYSIOTHERAPY; REVIEW; SIDE EFFECT; SPASTICITY; SYSTEMATIC REVIEW; TREATMENT OUTCOME; XEROSTOMIA;

EID: 12444310107     PISSN: 00195456     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02829820     Document Type: Review

References (61)

1. Davies LE. Botulinum toxin: from poison to medicine. Western J Med 1993; 158: 25-29.
2. Burgen ASV, Dickens F, Zatinam LJ. The action of botulinum toxin on the neuromuscular junction. J Physiol 1949; 109: 10-24.
3. de Paiva A, Meunier FA, Molgo J, Aoki KR, Dolly JO. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci USA 1999; 96: 3200-3205.
4. van Ermengen E. Uber einen neuen anaeroben bacillus and seine Beziehungen zum botulismus. Z Hyg Infektionskrank 1897; 26: 1-56. (In German)
5. Scott AB, Rosenbaum A, Collins CC. Pharmacological weakening of extraocular muscles. Invest Opthalmol Vis Sci 1973; 12: 924-927.
6. Scott AB. Botulinum toxin injection of eye muscles to correct strabismus. Trans Am Ophthalmol Soc 1981; 79:734-770.
7. Jankovic J, Brin MF. Botulinum toxin: historical perspective and potential new indications. Muscle Nerve 1997; (Suppl 6): S 125-S 145.
8. Brin MF. Botulinum toxin: new and expanded indications. Eur J Neurol 1997; 4: S 59-S 65.
9. Verheyden J, Blitzer A. Other noncosmetic uses of BOTOX. Dis Mon 2002; 48: 357-366.
10. Middlebrook JL. Cell surface receptors for protein toxins. In: Simpson LL, ed. Botulinum Neurotoxin and Tetanus Toxin. Academic Press, San Diego, 1989; 95-119.
11. Shaari CM, George E, Wu, BL Wu, Biller HF, Sanders I. Quantifying the spread of botulinum toxin through muscle fascia. Laryngoscope 1991; 101: 960-964.
12. Blasi J, Chapman ER, Link E, Binz T, Yamasaki S, De Camilli P et al. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP- 25. Nature 1993; 365: 160-163.
13. Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS et al. Working Group on Civilian Biodefense. Botulinum toxin as a biological weapon: medical and public health management. JAMA 2001; 285: 1059-1070.
14. Simpson LL. Botulinum toxin: potent poison, potent medicine. Hosp Pract 1999; 34: 87-91.
15. Hambleton P, Cohen HE, Palmer J, Melling J. Antitoxins and botulinum toxin treatment. BMJ 1992; 304: 959-960
16. Sanders DB, Massey EW, Buckley EG. Botulinum toxin for blepharospasm: single fibre EMG studies. Neurology 1986; 36: 545-547.
17. Hagberg B, Hagberg G. Origin of cerbral palsy. In David TJ et al., eds. Recent Advances in Pediatrics. No.11. London: Churchill livingston 1999: 67-83.
18. Dabney KW, Lipton GE, Miller F. Cerebral palsy. Curr Opin Pediatr 1997; 9: 81-88.
19. Koman LA, Smith BP, Shilt JS. Cerebral palsy. Lancet 2004; 363 : 1619-1631.
20. Gage JR. Clinics in developmental medicine, No.121. Gait analysis in cerebral palsy, Oxford: Mackeith Press, 1991.
21. Smith MF. Advances in the management of cerebral palsy. In David TJ, ed. Recent Advances in Pediatrics, No. 17. London: Churchill Livingstone, 1999: 129-140.
22. Hainsworth F, Harrison MJ, Sheldon TA, Roussounis SH. A preliminary evaluation of ankle orthoses in the management of children with cerebral palsy. Dev Med Child Neurol 1997; 39: 243-247.
23. Diamond M. Rehabilitation strategies for the child with cerebral palsy. Pediatr Ann 1986; 15: 230-234.
24. Botte MJ, Abrams RA, Bodine-Fowler SC. Treatment of acquired muscle spasticity using phenol peripheral nerve blocks. Orthopedics 1995; 18: 151-159.
25. Eames NW, Baker R, Hill N, Graham K, Taylor T, Cosgrove A. The effect of botulinum toxin A on gastrocnemius length: magnitude and duration of response. Dev Med Child Neurol 1999; 41: 226-232.
26. Eames NW, Baker R, Cosgrove A. Defining gastrocnemius muscle length in ambulant children. Gait Posture 1997; 6: 9-17.
27. Koman LA, Mooney JF 3rd, Smith B, Goodman A, Mulvaney T. Management of cerebral palsy with botulinum-A toxin: preliminary investigation. J Pediatr Orthop 1993; 13: 489-495.
28. Boyd RN, Hays RM. Current evidence for the use of botulinum toxin A in the management of children with cerebral palsy: a systematic review. Eur J Neurol 1993; 8: 1-20.
29. Koman LA, Mooney JF 3rd, Smith BP, Goodman A, Mulvaney T. Management of spasticity in cerebral palsy with botulinum-A toxin: report of a preliminary, randomized, double-blind trial. J Pediatr Orthop 1994; 14: 299-303.
30. Baker R, Jasinski M, Maciag-Tymecka I, Michalowska-Mrozek J, Bonikowski M, Carr L et al. Botulinum toxin treatment of spasticity in diplegic cerebral palsy: a randomized, double blind, placebo-controlled, dose-ranging study. Dev Med Child Neurol 2002; 44: 666-675.
31. Ubhi T, Bhakta BB, Ives HL, Allgar V, Roussounis SH. Randomised double blind placebo controlled trial of the effect of botulinum toxin on walking in cerebral palsy. Arch Dis Child 2000; 83: 481-487.
32. Corry IS, Cosgrove AP, Walsh EG, McClean D, Graham HK. Botulinum toxin A in the hemiplegic upper limb: a double-blind trial. Dev Med Child Neurol 1997; 39: 185-193.
33. Fehlings D, Rang M, Glazier J, Steele C. An evaluation of botulinum - A toxin injections to improve upper extremity function in children with hemiplegic cerebral palsy. J Pediatr 2000; 137: 331-337.
34. Barwood S, Baillieu C, Boyd R, Brereton K, Low J, Nattrass G et al. Analgesic effects of botulinum toxin A: a randomized, placebo-controlled clinical trial. Dev Med Child Neurol 2000; 42: 116-121.
35. Wissel J, Heinen F, Schenkel A, Doll B, Ebersbach G, Muller J et al. Botulinum toxin A in the management of spastic gait disorders in children and young adults with cerebral palsy: a randomized, double-blind study of high-dose versus low-dose treatment. Neuropediatrics 1999; 30: 120-124.
36. Polak F, Morton R, Ward C, Wallace WA, Doderlein L, Siebel A. Double-blind comparison study of two doses of botulinum toxin A injected into calf muscles in children with hemiplegic cerebral palsy. Dev Med Child Neurol 2002; 44: 551-555.
37. Corry IS, Cosgrove AP, Duffy CM, McNeill S, Taylor TC, Graham HK. Botulinum toxin A compared with stretching casts in the treatment of spastic equinus: a randomised prospective trial. J Pediatr Orthop 1998; 18: 304-311.
38. Flett PJ, Stern LM, Waddy H, Connell TM, Seeger JD, Gibson SK. Botulinum toxin A versus fixed cast stretching for dynamic calf tightness in cerebral palsy. J Paediatr Child Health 1999; 35: 71-77.
39. Desloovere K, Molenaers G, Jonkers I, De Cat J, De Borre L, Nijs J, Eyssen M, Pauwels P, De Cock P. A randomized study of combined botulinum toxin type A and casting in the ambulant child with cerebral palsy using objective outcome measures. Eur J Neurol 2001; 8: 75-87.
40. Hesse S, Jahnke MT, Luecke D, Mauritz KH. Short-term electrical stimulation enhances the effectiveness of Botulinum toxin in the treatment of lower limb spasticity in hemiparetic patients. Neurosci Lett 1995; 201: 37-40.
41. Detrembleur C, Lejeune TM, Renders A, van Den Bergh PY. Botulinum toxin and short-term electrical stimulation in the treatment of equinus in cerebral palsy. Mov Disord 2002; 17: 162-169.
42. Boyd RN, Dobson F, Parrott J, Love S, Oates J, Larson A et al. The effect of botulinum toxin type A and a variable hip abduction orthosis on gross motor function: a randomized controlled trial. Eur J Neurol 2001; 8: 109-119.
43. Koman LA, Paterson Smith B, Balkrishnan R. Spasticity associated with cerebral palsy in children: guidelines for the use of botulinum A toxin. Pediatr Drugs 2003; 5: 11-23.
44. Ade-Hall RA, Moore AP. Botulinum toxin type A in the treatment of lower limb spasticity in CP (Cochrane Review) In The Cochrane Library, Issue1. Chichester, UK: John Wiley and Sons. 2004.
45. Boyd RN, Graham HK. Botulinum toixn A in the management of children with cerebral palsy: indications and outcome. Eur J Neurol 1997; 4: S 15-S 22.
46. Graham HK, Aoki KR, Autti-Ramo I, Boyd RN, Delgado MR, Gaebler-Spira DJ et al. Recommendations for the use of botulinum toxin type A in the management of cerebral palsy. Gait Posture 2000; 11: 67-79.
47. Carr LJ, Cosgrove AP, Gringras P, Neville BG. Position paper on the use of botulinum toxin in cerebral palsy. Arch Dis Child 1998; 79: 271-273.
48. Gormley ME, Gaebler-Spira D, Delgado MR. Use of botulinum toxin type A in pediatric patients with cerebral palsy: a three-center retrospective chart review. J Child Neurol 2001; 16: 113-118.
49. O'Brien CF. Treatment of spasticity with botulinum toxin. Clin J Pain 2002; 18: S182-190.
50. Schwerin A, Berweck S, Fietzek UM, Heinen F. Botulinum toxin B treatment in children with spastic movement disorders: A pilot study. Pediatr Neurol 2004; 31: 109-113.
51. Brin MF, Lew MF, Adler CH, Comella CL, Factor SA, Jankovic J et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology 1999; 53: 1431-1438.
52. Montecucco C, Schiavo G, Tugnoli V, de Grandis D. Botulinum neurotoxins: mechanism of action and therapeutic applications. Mol Med Today 1996; 2: 418-424.
53. Naumann M, Jankovic J. Safety of Botulinum toxin type A: A systematic review and meta-analysis. Curr Med Res Opin 2004; 20: 981-990.
54. Brashear A, Lew MF, Dykstra DD, Comella CL, Factor SA, Rodnitzky RL et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology 1999; 53: 1439-1446.
55. Dressler D, Benecke R. Initial experiences with clinical use of botulinum toxin type B. Nervenarzt 2002; 73: 194-198.
56. Herrmann J, Mall V, Bigalke H, Geth K, Korinthenberg R, Heinen F. Secondary nonresponse due to development of neurtralising antibodies to Botulinum toxin A during treatment of children with cerebral palsy. Neuropediatrics 2000; 31: 333-334.
57. Kessler KR, Skutta M, Benecke R. Long-term treatment of cervical dystonia with botulinum toxin A: Efficacy, safety, and antibody frequency. German Dystonia Study Group. J Neurol 1999; 246: 265-274.
58. Tilton AH. Management of spasticity in children with cerebral palsy. Semin Pediatr Neurol 2004; 11: 58-65.
59. Berweck S, Heinen F. Use of botulinum toxin in pediatric spasticity (cerbral palsy) Mov Disord 2004; 19: S162-S167.
60. Jefferson RJ. Botulinum toxin in the management of cerebral palsy. Dev Med Child Neurol 2004; 46: 491-499.
61. Pidcock FS. The emerging role of therapeutic botulinum toxin in the treatment of cerebral palsy. J Pediatr 2004; 145: S33-S35.